加载中
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新数据
US$3.76
US$0.00 · -0.13%
Ironwood Pharmaceuticals, Inc. operates as a healthcare enterprise primarily dedicated to discovering, developing, and commercializing therapeutic solutions for gastrointestinal (GI) conditions. Its flagship commercial product is linaclotide, a guanylate cyclase type-C (GC-C) agonist. This medication is prescribed for adult patients managing irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), sold as LINZESS in the United States and Mexico, and under the CONSTELLA brand throughout Canada and the European Union. Beyond its marketed offerings, Ironwood's development pipeline includes IW-3300, another GC-C agonist targeting various visceral pain conditions, such as interstitial cystitis/bladder pain syndrome and endometriosis. Additionally, the company is advancing CNP-104, an immune nanoparticle being investigated for biliary cholangitis. Ironwood maintains key strategic alliances with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. to support the ongoing development and market introduction of linaclotide. Established in 1998, the Boston, Massachusetts-based firm initially operated as Microbia, Inc. before officially rebranding to Ironwood Pharmaceuticals, Inc. in April 2008.
最新数据
US$3.76
US$0.00 · -0.13%
盘中时间采用ET。市场数据可能有所延迟。
Ironwood Pharmaceuticals, Inc. operates as a healthcare enterprise primarily dedicated to discovering, developing, and commercializing therapeutic solutions for gastrointestinal (GI) conditions. Its flagship commercial product is linaclotide, a guanylate cyclase type-C (GC-C) agonist. This medication is prescribed for adult patients managing irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), sold as LINZESS in the United States and Mexico, and under the CONSTELLA brand throughout Canada and the European Union. Beyond its marketed offerings, Ironwood's development pipeline includes IW-3300, another GC-C agonist targeting various visceral pain conditions, such as interstitial cystitis/bladder pain syndrome and endometriosis. Additionally, the company is advancing CNP-104, an immune nanoparticle being investigated for biliary cholangitis. Ironwood maintains key strategic alliances with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. to support the ongoing development and market introduction of linaclotide. Established in 1998, the Boston, Massachusetts-based firm initially operated as Microbia, Inc. before officially rebranding to Ironwood Pharmaceuticals, Inc. in April 2008.
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
买入
估值
85
深度低估
情绪
57
多空交织
风险
46
风险偏高
动量
74
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Ironwood Pharmaceuticals, Inc. operates as a healthcare enterprise primarily dedicated to discovering, developing, and commercializing therapeutic solutions for gastrointestinal (GI) conditions. Its flagship commercial product is linaclotide, a guanylate cyclase type-C (GC-C) agonist. This medication is prescribed for adult patients managing irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), sold as LINZESS in the United States and Mexico, and under the CONSTELLA brand throughout Canada and the European Union. Beyond its marketed offerings, Ironwood's development pipeline includes IW-3300, another GC-C agonist targeting various visceral pain conditions, such as interstitial cystitis/bladder pain syndrome and endometriosis. Additionally, the company is advancing CNP-104, an immune nanoparticle being investigated for biliary cholangitis. Ironwood maintains key strategic alliances with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. to support the ongoing development and market introduction of linaclotide. Established in 1998, the Boston, Massachusetts-based firm initially operated as Microbia, Inc. before officially rebranding to Ironwood Pharmaceuticals, Inc. in April 2008.
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 2.96亿 USD | 3.51亿 USD | 4.43亿 USD | 4.11亿 USD | 4.14亿 USD |
| 销货成本 | — | 755.2万 USD | 614.8万 USD | 141.8万 USD | 7040.5万 USD |
| 毛利 | 2.96亿 USD | 3.44亿 USD | 4.37亿 USD | 4.09亿 USD | 3.43亿 USD |
| 研究与开发 | 9513.6万 USD | 1.11亿 USD | 1.16亿 USD | 4426.5万 USD | 7040.5万 USD |
| 销售、一般及管理费用 | 8225.6万 USD | — | — | 1.16亿 USD | — |
| 营业费用 | 1.77亿 USD | 2.51亿 USD | 13.82亿 USD | 1.59亿 USD | 1.11亿 USD |
| 利息收入 | 407.6万 USD | 446.8万 USD | 1897.1万 USD | 950.1万 USD | 72.6万 USD |
| 利息支出 | 3274.6万 USD | 3303.4万 USD | 2162.9万 USD | 759.8万 USD | 3115万 USD |
| 折旧和摊销 | 188.1万 USD | 201.1万 USD | 157.5万 USD | 141.8万 USD | 150万 USD |
| 营业利润 | 1.19亿 USD | 9312.4万 USD | −9.45亿 USD | 2.5亿 USD | 2.32亿 USD |
| 净利润 | 2401.7万 USD | 88万 USD | −10.02亿 USD | 1.75亿 USD | 5.28亿 USD |
公司数据更新于 2026年10月13日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$6.68
上涨空间 77.66%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2019年4月2日 | 597:500 | — | — |
已生效 2019年4月2日
597:500
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI2032.13万0.00%2.3万亿 USD0.03%US$381.07-0.13%
iShares Russell 2000 ETFIWM1583.56万0.02%787.4亿 USD0.19%US$276.5-0.50%
State Street SPDR S&P Biotech ETFXBI1248.97万0.13%103.03亿 USD0.35%US$149.18-1.47%
Vanguard Extended Market ETFVXF720.06万0.01%954亿 USD0.05%US$232.25-0.55%
iShares Russell 2000 Growth ETFIWO541.96万0.04%139.17亿 USD0.24%US$351.32-0.68%
Pacer US Small Cap Cash Cows ETFCALF502.74万0.14%35.87亿 USD0.59%US$55.185+0.78%
iShares Biotechnology ETFIBB472.8万0.04%108.2亿 USD0.44%US$202-1.11%
Dimensional - US Small Cap ETFDFAS446.76万0.01%338.04亿 USD0.31%US$78.025-0.19%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOPacer US Small Cap Cash Cows ETFCALFiShares Biotechnology ETFIBBDimensional - US Small Cap ETFDFASAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
